At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.
Scientific excellence that achieves new standards of care drives the company's work. Over 20 products are currently in clinical development addressing a variety of key medical needs. In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale. The company is one of a handful of biotechnology companies that has three licensed and dedicated biological bulk-manufacturing facilities, including its large-scale manufacturing plant in Research Triangle Park, NC, which is one of the world's largest cell culture facilities. An additional large-scale manufacturing plant is under construction in Hillerød, Denmark. Biogen Idec has sufficient commercial manufacturing capacity for its own pipeline, as well as potential partners' products. Biogen Idec is headquartered in Cambridge, MA and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in 1978, and IDEC Pharmaceuticals Corporation, founded in 1985. The company maintains research centers of excellence in San Diego, CA and Cambridge, MA. Biogen Idec has additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland and operates a global distribution network, which covers over 70 countries. The company currently employs approximately 3,900 people worldwide.
TechAtlas Group is a healthcare strategy and competitive analysis research group dedicated to studying various competitive areas in healthcare in order to identify all the relevant technologies (e.g. drugs, devices, diagnostics, and procedures) that are currently used and that are in development all over the world. We then research how physicians, patients, and institutions (e.g. insurance companies) make decisions when it comes to prescribing, using, and paying for various technologies and ultimately make sense of the competitive landscape to determine which companies are going in the right directions (developing a credible technology for a legitimate unmet need that will still be unmet by the time the technology reaches the market) and which are going in the wrong direction (development a non-credible technology or targeting a need that is either currently met or will be met by the time they get to market). Our approach to analyzing current and emerging technologies offers the state-of-the-art in competitive landscape mapping and equips business and research executives with the understanding of an entire competitive area that is required to intelligently conduct product development, program prioritization, and technology licensing. Our maps not only identify the companies and technologies most likely to address unmet needs but also highlight opportunities for new innovation, including new applications and non-obvious commercialization strategies for existing technologies.
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a fateful meeting in 1976, the two decided to start the first biotechnology company, Genentech. Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions, more than 100 projects in the pipeline and a long term plan for growth. Genentech's mission is to be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Genentech is committed to high standards of integrity in contributing to the best interests of patients, the medical profession, employees and communities, and to seeking significant returns to the stockholders, based on the continual pursuit of scientific and operational excellence.
Seahorse Bioscience provides industry-leading analytical instruments and cell-based assay stress test kits for biological research and drug discovery. The Seahorse Extracellular Flux (XF) Analyzer makes it easy to measure mitochondrial function and dysfunction in cells and isolated mitochondria, and monitor the interplay of oxidative phosphorylation and glycolytic pathways in a single experiment, label free, and in real-time. Scientists worldwide are advancing their research in understanding the role of cell metabolism in Neurodegeneration, Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Obesity, Diabetes, Metabolic Disorders, Screening, and Translational Medicine. Founded in 2001, Seahorse Bioscience is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark; and Shanghai, China.